Yasuaki Muramatsu

Palbociclib in combination with letrozole in patients with estrogen receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer: PALOMA-2 subgroup analysis of Japanese patients

H. Iwata, C. Shimizu, H. Mukai, 2018, International Journal of Clinical Oncology.

Palbociclib in combination with fulvestrant in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: PALOMA-3 subgroup analysis of Japanese patients

F. Hara, H. Iwata, H. Mukai, 2018, International Journal of Clinical Oncology.

Analysis of subsequent therapy in Japanese patients with hormone receptor‒positive/human epidermal growth factor receptor 2‒negative advanced breast cancer who received palbociclib plus endocrine therapy in PALOMA-2 and -3

H. Iwata, C. Shimizu, H. Mukai, 2020, Breast Cancer.

Neutropenia management with palbociclib in Japanese patients with advanced breast cancer

H. Iwata, H. Mukai, Kenichi Inoue, 2019, Breast cancer.

Palbociclib‐letrozole as first‐line treatment for advanced breast cancer: Updated results from a Japanese phase 2 study

H. Iwata, Kenichi Inoue, N. Masuda, 2020, Cancer medicine.

Palbociclib in combination with letrozole as first‐line treatment for advanced breast cancer: A Japanese phase II study

H. Iwata, Kenichi Inoue, N. Masuda, 2018, Cancer science.

Real-world treatment patterns of subsequent therapy after palbociclib in patients with advanced breast cancer in Japan

H. Iwata, K. Togo, M. Sawaki, 2023, Breast.

Overall survival in Japanese patients with ER+/HER2− advanced breast cancer treated with first-line palbociclib plus letrozole

N. Masuda, H. Yasojima, Yasuaki Muramatsu, 2023, Breast cancer.